Comparison of antegrade cardioplegia and retrograde cardioplegia in myocardial protection during isolated aortic valve replacement

Comparison of antegrade cardioplegia and retrograde cardioplegia in myocardial protection during isolated aortic valve replacement - ACDRCD test

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058254

Enrollment

160

Registered

2025-06-24

Start date

2024-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis and regurgitation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients received IIACD during AVR between April 1, 2016, and December 31, 2021. Patients received CHRCD during AVR between January 1, 2007, and March 31, 2015.

Exclusion criteria

Exclusion criteria: Excluding criteria was emergency cases, those involving concomitant valve surgeries, coronary artery bypass grafting, aortic repair, or the use of both antegrade and retrograde cardioplegia.

Design outcomes

Primary

Measure	Time frame
The primary outcome was the peak creatine kinase-MB (CK-MB) level in peripheral blood within one week postoperatively.	—

Secondary

Measure	Time frame
Secondary outcomes were echocardiographic parameters such as ejection fraction (EF), wall motion, and degree of regurgitation at the mitral and tricuspid valves. Echocardiography was performed approximately one week after surgery.	—

Countries

Japan

Contacts

Public ContactJUNJI NAKAZAWA

Sapporo Medical University of Medicine Department of Cardiovascular Surgery

bankara02@gmail.com0116112111

Outcome results